Ipamorelin

Ipamorelin is a synthetic growth hormone secretagogue. A 1998 paper described it as the first selective compound of this type. Research has focused on its selectivity. It stimulates growth hormone release with minimal reported effect on cortisol or prolactin, which set it apart from earlier secretagogues with broader hormonal activity. It is sold for laboratory research use only.

Research describes Ipamorelin as an agonist at the ghrelin receptor, GHS-R1a. Activating this receptor has been studied as a way to stimulate growth hormone release from the pituitary. Research has also explored whether Ipamorelin produces a pulsatile release pattern that resembles the body's own growth hormone rhythm. Its selectivity for growth hormone over cortisol and prolactin is the feature most often examined.

Early studies examined its selective growth hormone releasing activity. A 1999 study in rats reported that it induced longitudinal bone growth. More recent reviews discuss Ipamorelin alongside other growth hormone secretagogues in body composition research, orthopaedic and sports medicine, and healthy aging. These reviews generally frame it as an investigational compound, and controlled human outcome data remain limited.

Human safety data for Ipamorelin are limited. Early research emphasized its minimal effect on cortisol and prolactin compared with earlier secretagogues. Recent reviews assess the safety and efficacy of unapproved peptide therapies, including compounds of this class. Other reviews examine its use in recreational and professional sport and bodybuilding in a doping context. Adverse events are not comprehensively summarized in the cited studies.

Research protocols have used 200–500 mcg per administration, 5 days per week, in the evening in a fasted state. These protocols ran in 8-week blocks followed by 4 weeks off, and the route described is subcutaneous. These figures describe research protocols only. Each CoreX order ships with a protocol guide for laboratory reference.